Avalo Therapeutics AVTX Pre-Tax Income
Pre-Tax Income at other companies
Other financials
Where this comes from
Reported directly by Avalo Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest.
The official record: Avalo Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Avalo Therapeutics's pre-tax income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Avalo Therapeutics's pre-tax income?
- Avalo Therapeutics (AVTX) reported pre-tax income of -$19.62M in Q1 2026.
- How has Avalo Therapeutics's pre-tax income changed year-over-year?
- Avalo Therapeutics's pre-tax income decreased by 49.3% year-over-year, from -$13.14M to -$19.62M.
- What is the long-term trend for Avalo Therapeutics's pre-tax income?
- Over 3 years (2022 to 2025), Avalo Therapeutics's pre-tax income has grown at a 23.3% compound annual growth rate (CAGR), from -$41.63M to -$78.09M.
- What does pre-tax income mean?
- Total income from all sources — operating income plus non-operating items like interest income, investment gains, and other income — before the provision for income taxes.